[分析口腔癌患者的炎症参数和临床特征之间的相关性]
1Department of Head and Neck Surgery, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, China.
概括
增加的炎症标志物,如中性粒细胞与淋巴细胞的比率 (NLR),血小板与淋巴细胞的比率 (PLR) 和全身炎症指数 (SII),可能会降低HPV阳性口腔状细胞癌 (OPSCC) 的生存益处. SII和PLR可以帮助预测HPV状态和转移风险.
科学领域:
- 在瘤学瘤学.
- 炎症标志物的炎症标志物
- 口腔甲状腺状细胞癌 (OPSCC)
背景情况:
- 口腔状细胞癌 (OPSCC) 的预后受到HPV状况的影响.
- 治疗前的炎症标志物,包括中性粒细胞与淋巴细胞的比率 (NLR),单细胞与淋巴细胞的比率 (MLR),血小板与淋巴细胞的比率 (PLR),全身炎症反应指数 (SII) 和全身炎症反应指数 (SIRI),越来越多地被认为是它们在各种癌症中的潜在预后价值.
研究的目的:
- 调查OPSCC患者的临床特征.
- 探索临床特征与治疗前的炎症参数 (NLR,MLR,PLR,SII,SIRI) 之间的关系.
- 评估这些炎症标志物对与HPV (p16) 状态有关的预后的影响.
主要方法:
- 从2017年1月到2024年1月,对149名OPSCC患者的临床数据进行了回顾性分析.
- 患者被分为p16阳性 (HPV阳性) 和p16阴性 (HPV阴性) 组.
- 统计分析 (SPSS 29.0) 用于评估炎症参数,临床因素和预后之间的相关性.
主要成果:
- 56.4%的OPSCC患者是p16阳性;p16状态是一个独立的预后因素 (P=0.038).
- 升高的NLR,PLR和SII并没有显著改变p16阳性和p16阴性组之间的预后差异.
- 在p16阳性患者中,治疗前的SII显著更高 (P=0.005),升高的PLR与更高的淋巴结转移风险相关 (P=0.029).
结论:
- 升高的NLR,PLR和SII可能会降低HPV阳性OPSCC的预后优势.
- 在OPSCC中,SII和PLR显示出作为HPV感染状态的预测因素的潜力.
- 在OPSCC患者中,PLR可能是评估宫淋巴结转移风险的有价值指标.
相关概念视频
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
507
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
507
01:21Cancer Survival Analysis
629
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
629